Key result
Higher preoperative Gal-3 and ALD levels independently predicted AF recurrence after RFCA, with combined high levels yielding a 57% recurrence rate versus 9% for low levels (p<0.01).
Why the study?
The potential value of circulating galectin-3 and aldosterone as predictors of atrial fibrillation recurrence after radiofrequency catheter ablation is unknown or controversial.
Do preoperative circulating Gal-3 and ALD levels predict atrial fibrillation recurrence in patients undergoing radiofrequency catheter ablation?
Cohort (n=153)
Do preoperative circulating Gal-3 and ALD levels predict atrial fibrillation recurrence in patients undergoing radiofrequency catheter ablation?
Hazard Ratio: 1.28 (95% CI 1.04–1.56)
Absolute Event Rate: 35% vs 12%
p-value: p=0.02
Preoperative circulating Gal-3 and ALD levels independently predict AF recurrence after radiofrequency catheter ablation, with their combination offering high predictive accuracy.
Higher baseline Gal-3 and ALD may flag post-RFCA recurrence risk; leaves open their value as predictors pending prospective studies.
Background. Circulating galectin-3 (Gal-3) and aldosterone (ALD) are involved in fibrosis and inflammation. However, their potential value as predictors of atrial fibrillation (AF) recurrence after radiofrequency catheter ablation (RFCA) is unknown or controversial. Therefore, the aim of this study was to assess the relationship between baseline Gal-3, ALD levels, and AF recurrence in patients performing RFCA. Methods. 153 consecutive patients undergoing RFCA were included. Gal-3 and ALD were measured at baseline. Univariate and multivariate Cox regressions were performed to determine the predictors of AF recurrence. Receiver operating characteristic (ROC) curve and Kaplan-Meier (K-M) curve were used to assess the value of predictors. Results. There were 35 (22.88%) cases of AF recurrence after RFCA. The recurrence group had significantly higher preoperative serum levels of Gal-3 and ALD than the nonrecurrence group. Univariate and multivariate analysis showed that Gal-3 ( <a:math xmlns:a="http://www.w3.org/1998/Math/MathML" id="M1"> <a:mtext>HR</a:mtext> <a:mo>=</a:mo> <a:mn>1.28</a:mn> </a:math> , 95% CI: 1.04-1.56, <c:math xmlns:c="http://www.w3.org/1998/Math/MathML" id="M2"> <c:mi>p</c:mi> <c:mo>=</c:mo> <c:mn>0.02</c:mn> </c:math> ) and ALD ( <e:math xmlns:e="http://www.w3.org/1998/Math/MathML" id="M3"> <e:mtext>OR</e:mtext> <e:mo>=</e:mo> <e:mn>1.02</e:mn> </e:math> , 95% CI: 1.00-1.03, <g:math xmlns:g="http://www.w3.org/1998/Math/MathML" id="M4"> <g:mi>p</g:mi> <g:mo><</g:mo> <g:mn>0.03</g:mn> </g:math> ) were significantly associated with AF recurrence after RFCA. The area under the curve (AUC) of preoperative serum Gal-3, ALD, and 2 combined to predict the recurrence of AF patients after RFCA was 0.636, 0.798, and 0.893, respectively, while sensitivity was 65.32%, 71.69%, and 88.61%, respectively and specificity was 77.46%, 78.53%, and 86.0%, respectively. Patients with Gal-3 above the cutoff value of 14.57 pg/ml had higher frequent AF recurrence than the patients with <i:math xmlns:i="http://www.w3.org/1998/Math/MathML" id="M5"> <i:mtext>Gal</i:mtext> <i:mo>−</i:mo> <i:mn>3</i:mn> <i:mo>≤</i:mo> <i:mn>14.57</i:mn> <i:mtext> </i:mtext> <i:mtext>pg</i:mtext> <i:mo>/</i:mo> <i:mtext>ml</i:mtext> </i:math> (35% vs. 12%, <k:math xmlns:k="http://www.w3.org/1998/Math/MathML" id="M6"> <k:mi>p</k:mi> <k:mo><</k:mo> <k:mn>0.001</k:mn> </k:math> ) during a follow-up. Meanwhile, patients with ALD above the cutoff value of 243.61 pg/ml also had a higher AF recurrence rate than those with <m:math xmlns:m="http://www.w3.org/1998/Math/MathML" id="M7"> <m:mtext>ALD</m:mtext> <m:mo>≤</m:mo> <m:mn>243.61</m:mn> <m:mtext> </m:mtext> <m:mtext>pg</m:mtext> <m:mo>/</m:mo> <m:mtext>ml</m:mtext> </m:math> (37% vs. 11%, <o:math xmlns:o="http://www.w3.org/1998/Math/MathML" id="M8"> <o:mi>p</o:mi> <o:mo><</o:mo> <o:mn>0.001</o:mn> </o:math> ) during a follow-up. The recurrence rate in patients with <q:math xmlns:q="http://www.w3.org/1998/Math/MathML" id="M9"> <q:mtext>Gal</q:mtext> <q:mo>−</q:mo> <q:mn>3</q:mn> <q:mo>></q:mo> <q:mn>14.57</q:mn> <q:mtext> </q:mtext> <q:mtext>pg</q:mtext> <q:mo>/</q:mo> <q:mtext>ml</q:mtext> <q:mo>+</q:mo> <q:mtext>ALD</q:mtext> <q:mo>></q:mo> <q:mn>243.61</q:mn> <q:mtext> </q:mtext> <q:mtext>pg</q:mtext> <q:mo>/</q:mo> <q:mtext>ml</q:mtext> </q:math> was higher than that in patients with baseline <s:math xmlns:s="http://www.w3.org/1998/Math/MathML" id="M10"> <s:mtext>Gal</s:mtext> <s:mo>−</s:mo> <s:mn>3</s:mn> <s:mo>></s:mo> <s:mn>14.57</s:mn> <s:mtext> </s:mtext> <s:mtext>pg</s:mtext> <s:mo>/</s:mo> <s:mtext>ml</s:mtext> </s:math> or <u:math xmlns:u="http://www.w3.org/1998/Math/MathML" id="M11"> <u:mtext>ALD</u:mtext> <u:mo>></u:mo> <u:mn>243.61</u:mn> <u:mtext> </u:mtext> <u:mtext>pg</u:mtext> <u:mo>/</u:mo> <u:mtext>ml</u:mtext> </u:math> and patients with <w:math xmlns:w="http://www.w3.org/1998/Math/MathML" id="M12"> <w:mtext>Gal</w:mtext> <w:mo>−</w:mo> <w:mn>3</w:mn> <w:mo>≤</w:mo> <w:mn>14.57</w:mn> <w:mtext> </w:mtext> <w:mtext>pg</w:mtext> <w:mo>/</w:mo> <w:mtext>ml</w:mtext> <w:mo>+</w:mo> <w:mtext>ALD</w:mtext> <w:mo>≤</w:mo> <w:mn>243.61</w:mn> <w:mtext> </w:mtext> <w:mtext>pg</w:mtext> <w:mo>/</w:mo> <w:mtext>ml</w:mtext> </w:math> (57% vs. 14% vs. 9%, <y:math xmlns:y="http://www.w3.org/1998/Math/MathML" id="M13"> <y:mi>p</y:mi> <y:mo><</y:mo> <y:mn>0.01</y:mn> </y:math> , respectively). Conclusion. AF recurrence after RFCA had higher baseline Gal-3 and ALD levels, and higher preoperative circulating Gal-3 and ALD levels were independent predictors of AF recurrence for patients undergoing RFCA, while combination of preoperative Gal-3 and ALD levels has higher prediction accuracy.
No takes yet. Share an insight, caveat, or question.
Ruan et al. (2022) conducted a cohort in Atrial fibrillation (n=153). Elevated preoperative Galectin-3 (Gal-3) and aldosterone (ALD) levels vs. Lower levels of Gal-3 and ALD was evaluated on Atrial fibrillation recurrence (HR 1.28, 95% CI 1.04-1.56, p=0.02). Higher preoperative Gal-3 and ALD levels independently predicted AF recurrence after RFCA, with combined high levels yielding a 57% recurrence rate versus 9% for low levels (p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: